Consequently, combining nucleolin inhibitor (aptamer AS1411) with doxorubicin greatly reduces the survival chance of DLBCL cells by compromising DNA repair capabilities provided by TopIIA. This evidence concerns the gene TOP2A and diffuse large B-cell lymphoma.